Transfer of drug resistance genes into hematopoietic stem cells (HSCs) has promise for the treatment of a variety of inherited, that is, X-linked severe combined immune deficiency, adenosine deaminase deficiency, thalassemia, and acquired disorders, that is, breast cancer, lymphomas, brain tumors, and testicular cancer. Drug resistance genes are transferred into HSCs either for providing myeloprotection against chemotherapy-induced myelosuppression or for selecting HSCs that are concomitantly transduced with another gene for correction of an inherited disorder. In this review, we describe ongoing experimental approaches, observations from clinical trials, and safety concerns related to the drug resistance gene transfer.
G ene transfer into hematopoietic stem cells (HSCs) has promise as a novel treatment for some inherited and acquired disorders. HSCs are highly desirable for gene therapy, because of their self-renewal and multilineage differentiation capacities, and so stable engraftment of genetically modified HSCs leads to adequate expression of transgene in stem and progenitor cells. Additionally, HSCs are easy to access for harvest and delivery. However, early results defined a variety of problems such as low efficiency of gene transfer, 1-9 low long-term expression, 7-13 engraftment failure of ex vivo-manipulated HSCs, [14] [15] [16] [17] immune response to transduced hematopoietic clones, 1,18-22 and silencing of the transgene. [23] [24] [25] [26] The ability to achieve efficient gene transfer to repopulating human HSCs and to maintain appropriate levels of expression in vivo in these cells and their progeny has been poor and the resultant clinical benefits negligible. New vectors and improvements in vector design, that is, lentivirus, foamy virus, and in vitro-packaged SV40 vectors, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] and envelope proteins, 10,27,38-47 use of the CH-296 domain of fibronectin in transduction, [48] [49] [50] [51] [52] [53] [54] [55] [56] improved cytokine combinations, 52, [56] [57] [58] [59] and changes in transduction methodology, that is, spinoculation and vector preloading, 43, 51, 56, [59] [60] [61] [62] [63] [64] [65] have improved gene transfer efficiency. 66, 67 Improvement in gene transfer technology and the survival advantage of transduced HSCs resulted in the success of HSC gene therapy in patients with X-linked severe combined immune deficiency (X-SCID). However, retrovirus integration in three X-SCID patients was associated with the development of T-cell acute lymphoblastic leukemia (T-ALL). [68] [69] [70] Integrational mutagenesis-related safety concerns caused the FDA to put a hold on gene therapy clinical trials for almost a year, and after extensive re-evaluation of accessible data, new safety guidelines were defined. Nevertheless, safety issues continue to be a concern and in a recent consensus workshop of American Society of Gene Therapy, 71 it was suggested that patients receiving HSCs transfected with oncoretroviral or lentiviral constructs should have a longterm follow-up plan of 15 years. Despite these safety concerns, the encouraging results obtained with the retroviral construct used to correct the defect in these X-SCID children, and from further improvements in gene transfer efficiency into HSCs, have provided a strong rationale to continue this program, in particular the use of HSC gene transfer technology to establish drugresistant hematopoiesis. 72 The potential benefits are clear: in those malignancies in which dose intensity increases response, protection of hematopoietic progenitors by gene transfer may allow higher and more effective doses of drug(s) to be administered, and more cures. Drug or drug combinations that are proposed for post-transplant chemotherapy, as they are non-cross-resistant to the previously applied treatments, should have minimal nonhematopoietic drug toxicity and a steep doseresponse curve.
Drug resistance gene transfer for myeloprotection
The concept of bone marrow (BM) protection, or myeloprotection, has emerged directly from our understanding of acquired drug resistance mechanisms in cancer cells. Malignant cells acquire resistance to a variety of antineoplastic agents, while the normal host cells do not. Certain mutants typically fail to bind the target drug or have decreased affinity, and yet demonstrate relatively uncompromised catalytic activity despite drug exposure. We and others have cloned several drug resistance genes and utilized these mutants for transduction into hematopoietic stem cells to generate resistance.
1, [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] Myeloprotection-based gene therapy strategies have led to many preclinical studies 81, 84, [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] and a few clinical studies.
1,7,9,98 Heterogeneity and growth kinetics of a given tumor rarely allow clinicians to depend on a single drugbased regimen. Certain drug resistance genes, for example, the multidrug resistance gene 1 (MDR1), or multidrug resistance-associated protein 1 (MRP1) gene could provide resistance to a variety of chemotherapeutics that could be used in combination. 1, 82, 85, 86, [99] [100] [101] [102] Expressing more than one drug resistance gene to protect against a combination of chemotherapeutic drugs could be of great therapeutic benefit. These genes may be expressed from a single promoter in order to circumvent the issues of different transcriptional efficiencies of different promoters or may be expressed from the same promoter but as separate translational units by the use of internal ribosomal entry site (IRES) elements. [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] Another approach would be to use fusion genes. 103, 110, 113 For example, a fusion gene encoding a double mutant of human dihydrofolate reductase (dmDHFR) and cytidine deaminase (CD) when transfected into mammalian cells protected them from both methotrexate (MTX) and cytarabine (Ara-C). 113 We have recently constructed a fusion gene comprised of the double mutant of DHFR (the F/S DHFR) and a mutant form of the human thymidylate synthase (G52S TS) to confer dual resistance to MTX and 5FU that may be useful in myeloprotection strategies in breast cancer. 110 Although high-dose chemotherapy followed by ASCT has not been shown to improve outcome in breast cancer patients, except for a small subset, 115, 116 gene transfer making possible the addition of post-transplant chemotherapy with noncrossresistant drugs may be worthy of studying. Other laboratories have reported vectors containing MDR1 and O 6 methylguanine-DNA-methyltransferase (MGMT) that confer resistance against several chemotherapeutic agents. 117 The drug resistance genes that confer resistance to a variety of different drugs are summarized in Table 1 .
Although several cDNAs have been described that may impart a drug resistance phenotype to HSCs (vide supra), thus far clinical studies have only been published using MDR1 CDNA.
1,7,9, 98 In this review, we summarize these studies as well as the rationale for the recently initiated clinical studies with a mutant MGMT CDNA that imparts resistance to nitrosoureas, and our soon to be initiated studies with a mutant DHFR-CD fusion cDNA to impart resistance to both MTX and Ara-C/gemcitibine.
Multidrug resistance gene (MDR1)
This gene encodes P-glycoprotein, a membrane protein that has been extensively studied, as overexpression is associated with resistance to a wide variety of structurally unrelated natural products that are in clinical use to treat cancer. [118] [119] [120] These include the taxanes (paclitaxel and taxotere), the vinca alkaloids (vinblastine, vincristine, and vinorelbine), anthracylines (doxorubicin and daunorubicin), and epipodophylotoxins (etoposide). MDR1-mediated chemoprotection in transgenic mice 121, 122 and in animals transplanted with retrovirally transduced BM 100,123 provided a strong rationale for MDR-1 gene therapy trials. Although a myeloproliferative disorder was observed in mice reconstituted with BM cells transduced with MDR1, 123, 124 this event has not been encountered in non-human primate studies and in human trials 1, 7, 9, 98, 99 as yet, but additional follow-up is required. Early studies did not show significant marking and expression, 7,9,98 but the study reported in 2000, discussed below, based on a better understanding of retroviral gene transfer into hematopoietic stem cells has provided evidence that it is possible to achieve long-term gene transfer into hematopoietic stem cells. patients with breast cancer who had achieved a partial or complete remission after chemotherapy had their peripheral blood HSCs harvested after mobilization with high-dose cyclophosphamide and granulocyte colony stimulating factor (G-CSF). CD34 þ cells were isolated and incubated for 72 hours with a retroviral construct using the pG1 Moloney murine leukemia virus (MoMLV) backbone with human MDR1 cDNA inserted. The cytokines used to stimulate stem cells into cycle were stem cell factor (SCF), interleukin 3 (IL-3), and interleukin 6 (IL-6). Only one-third of the CD34 þ cells were transduced. After a conditioning regimen containing high-dose ifosfamide, carboplatin, and etoposide, all of the CD34 þ cells were infused for rescue. The ex vivo transduction efficiency was only 0.1-0.5%. Three of the four patients receiving the infusion of the CD34 þ cells containing the transgene and who were treated with posttransplant paclitaxel had evidence of low-level engraftment; a correlation was observed between the relative number of granulocytes containing the MDR1 transgene and the granulocyte nadir after paclitaxel chemotherapy. The authors concluded that although this study demonstrated that engraftment of HSCs transduced with the MDR1 gene can be achieved, ''the overall transduction efficiency and stable engraftment of gene-modified HSCs must be improved before MDR1 gene therapy and in vivo selection with anticancer drugs may be reliably used to protect cancer patients from drug-related myelosuppression''. The second study differed from the previous one in several respects. 8 All of the CD34 þ cells transduced with the viral supernatants were reinfused and the transduction was accomplished without the use of added cytokines, and was supported by autologous BM stroma. The rationale used for the use of BM stroma without cytokines was that the stimulation of cell division by the previously used cytokines might have caused loss of stem cells by differentiation. The conditioning regimen used was single agent thiotepa -the hope was that this drug would be less toxic to the tumor microenvironment than the previously used chemotherapy cocktail. Also, in this study, to demonstrate selection, peripheral blood HSCs were transduced with either MDR1 or the bacterial NeoR gene. Following infusion of the transduced cells, the six patients with breast cancer were treated with MDR chemotherapy (paclitaxel, doxorubicin, and vinblastine). The mean transduction efficiency after incubation with the G1MD vector (MDR1) was 0.26%, while the transduction efficiency with the Neo vector (G1Na) was 30.3% -partially explained by the 6-to 10-fold higher titer of the G1Na viral supernatant, and also due to the presence of a cryptic splice site in the G1MD vector that rendered half of the G1MD provirus undetectable by the PCR assay used, because of a large deletion in the coding region. Despite the fact that the transduction efficiency of the NeoR vector was much higher than the transduction efficiency of the MDR1 vector, the MDR1 gene was detected more frequently and at higher levels than the NeoR gene. In the six patients, the level of MDR1 marking in granulocytes ranged from 0.01 to 1.0%, while only three patients showed intermittent NeoR marking and none showed sustained engraftment with NeoR. Of interest, two of the patients showed evidence of transient in vivo selection. However, the low transduction efficiency observed, possibly due to the viral titer or to the conditions of the transduction, was disappointing.
A third more encouraging study also reported in 1999 by Abonour et al 1 differed from the previous two studies described in that these investigators utilized a recombinant fibronectin fragment CH-296 to colocalize retroviral particles to HSCs and to increase transduction efficiencies. A total of 12 patients with germ cell tumors were tandemly transplanted; the first transplant was with unmanipulated marrow, and the second transplant was with CD34 þ -selected cells, stimulated with cytokines and then transduced with an MDR1 containing retroviral vector in the presence of recombinant fibronectin fragment, CH-296. Transduction was accomplished over a 5-day period. Cells were cultured with SCF and IL-6 in the first 10 patients and with SCF, megakaryocyte growth and development factor, and G-CSF in the last two patients. The MDR1 vector was added on days 3 and 4, and cells were cryopreserved and returned to the patients after the conditioning regimen (etoposide and carboplatin). Post-transplant, patients were treated with oral etoposide daily for 21 consecutive days every 3 weeks for three cycles. The use of a fibronectin fragment and these culture conditions to transduce the stem cells resulted in the highest level of gene transfer reported thus far in marrow progenitors (up to 15% in 1 year). Evidence for in vivo selection was present: a three-to nine-fold increase in transgene carrying peripheral blood leukocytes was observed after several cycles of chemotherapy. Of importance, these studies also showed that exposure of the CD34 þ cells to CH-269 and the 5-day exposure to the cytokines and retrovirus did not adversely affect engraftment kinetics. In addition, hematopoietic function remained normal in the eight surviving patients with a 2-year follow-up at that time.
Overall, the success with MDR1 gene transfer into HSCs was limited not only due to low gene expression but also due to truncation of the MDR1 gene by cryptic splicing. 125, 126 Sequence modifications to eliminate cryptic splice sites that compromise therapeutic virus production and MDR1 expression have made better MDR1 constructs available for gene therapy. 127, 128 Recent studies demonstrated better transduction rates of NOD/SCID repopulating human HSCs with these MDR1 constructs, and increased drug tolerance and selection of the gene.
129-131
O 6 -methylguanine-DNA-methyltransferase (MGMT)
A clinical study has been initiated by Gerson and coworkers, 132 using a mutated MGMT (MGMT-G156-A) CDNA to express the DNA repair enzyme O 6 -alkylguanine-DNA-alkyl transferase (AGT) for HSC protection in patients with solid tumors, brain tumors, or nonHodgkin's lymphoma (NHL). The rationale for this approach is that this enzyme protects both certain tumors and normal cells from cytotoxicity to nitrosourea compounds, including carmustine, temozolomide, and dacarbazine. An inhibitor of AGT, O 6 -benzyl guanine (BG), has been developed that depletes AGT in human tumors, and is nontoxic. While treatment of patients with this inhibitor would sensitize tumor cells to the nitrosoureas, it may also be expected to increase marrow toxicity. By utilizing a cDNA of MGMT with a mutation within the active site region, the AGT protein expressed is rendered resistant to BG inactivation, while still functioning to protect HSCs from toxicity to these agents. 92 A series of mutants have been developed in the MGMT cDNA that result in resistance to BG. The two MGMT mutants, G156A or P140K, 133 have retained repair activity and also provide resistance to BG. These mutants have been used in animal studies, and HSCs transduced with retroviral constructs containing these mutant cDNAs have increased tolerance to BG and BCNU. 63, 92, [133] [134] [135] [136] [137] [138] Of importance, in mice transplanted without ablation, selection was observed, up to 1000-fold in favor of the transduced cells. 134 These data are consistent with the possibility that selection has occurred at the stem cell level, and that myeloablation may not be required for selection in the clinic. In another study, human tumor bearing mouse recipients of marrow transduced with a mutant MGMT gene tolerated BG and BCNU to a greater degree than mice transplanted with lacZ carrying BM. 139 Phase II studies with BG and BCNU are in progress and additional studies are planned with temozolomide, thus providing the background information for the clinical gene therapy trial in progress at Western Reserve. 92 The advantage of using MDR1 and muMGMT in HSC gene transfer is that some of the drugs used for selection are actually capable of eliminating untransduced primitive HSCs. In this regard, muMGMT has also an advantage over MDR1. Inactivators, like BG, may ablate endogenous/or wild-type MGMT levels in untransduced HSCs, while endogenous MDR1 expression levels of some HSCs could be relatively high. The disadvantage of nitrosoureas for muMGMT-transduced HSCs is also the same; these chemotherapeutics are stem cell poisons and they are carcinogenic. However, the risk for developing leukemia may not be any greater than treatment with BCNU or temozolomide without marrow protection. 140, 141 Another drawback with the use of these agents is their limited antitumor efficacy in the clinic. Earlier studies pushing these drugs to maximally tolerated doses with autologous BM rescue did not improve the cure rate of patients with glioblastoma. [142] [143] [144] Dihydrofolate reductase (DHFR)7cytidine deaminase (CD)
The primary target of MTX is the enzyme DHFR, which catalyzes the reduction of folate and 7,8-dihydrofolate to 5,6,7,8-tetrahydrofolate. Different DHFR mutants have been widely used for conferring resistance to anti-folates, and are used as selectable markers in vitro and in vivo in the context of gene therapy. 73, [145] [146] [147] [148] In general, these mutants carry single amino-acid substitutions in the active site of DHFR. A transgenic mouse model carrying a mutant DHFR gene resistant to MTX protected the marrow as well as the gastrointestinal mucosa from MTX toxicity. 146, 147, [149] [150] [151] [152] BM from drug-resistant tyrosine-22 DHFR carrying transgenic animals transplanted to wild-type mice not only conferred substantial MTX tolerance but also provided a therapeutic index increase, which consequently enhanced 32Dp210 chronic myeloid leukemia elimination in the recipient animals. 153 We generated a double mutant DHFR by site-directed mutagenesis with substitutions of both Leu22 and Phe31 (Phe22-Ser31, F/S DHFR), which has greatly diminished affinity for anti-folates but only slightly reduced substrate affinity. 154 This double mutant provides a high level of MTX resistance following retrovirus-mediated gene transfer in NIH3T3 cells, 154 and mouse and human HSCs. In a mouse mammary tumor (E0771) model, animals transplanted with mutant DHFR CDNA-transduced BM were able to tolerate high-dose MTX treatment post-transplant, and 44% of the mice had no demonstrable tumor, while the control group of mice transplanted but not treated with MTX succumbed to tumor regrowth. 155 Ara-C is an antimetabolite that is primarily inactivated by deamination by CD. Retroviral transfection of CD in murine fibroblasts resulted in increased resistance to cytidine analogs. 156 Several in vitro studies have shown that Ara-C has significant synergistic antitumor activity when given with MTX. 157, 158 Simultaneous administration of Ara-C and MTX is associated with greater retention of Ara-CTP, associated with an improved therapeutic outcome when compared to either drug alone, or in sequence separated by 424 hours. 159 Several experimental systems have shown that cell kill from Ara-C is maximized when DNA synthesis is at a peak, as is often the case in the recovery period following exposure to other classes of cytotoxic agents. 160, 161 A novel fusion gene consisting of double mutant DHFR (F/S DHFR) and CD cDNAs was constructed in our laboratory and found to retain enzymatic characteristics of both enzymes. 113 As the fusion gene conferred high levels of resistance to both MTX (41000-fold) and Ara-C (five-to eight-fold), this vector was considered to be of value in protecting hematopoietic progenitors from the toxicity of these antimetabolites. The fusion gene (F/S DHFR-CD)-transduced BM provided myeloprotection and consequently a survival advantage in a congenic mouse model. 162 In relapsed or refractory NHL patients, the ifosfamide, carboplatin, and etoposide (ICE)/or ICE with rituximab regimen is a highly effective cytoreduction and peripheral blood stem cell mobilization regimen. 163, 164 However, following subsequent myeloablation regimens and autologous transplant, at a median follow-up of 4 years, the progression-free survival and overall survival are 28 and 34% by intention to treat and 39 and 45% for only those patients with chemosensitive disease. 165 Early relapse is more frequent in patients transplanted for advanced lymphoma, 166 and median time to relapse is about 5 months after transplant. [167] [168] [169] The administration of non-crossresistant therapies during the post-transplant phase could possibly eradicate residual disease and improve this cure rate. MTX and Ara-C have been widely used in combination for treatment of patients with NHL. [170] [171] [172] [173] [174] After tumor regression following conditioning regimens, some tumor cells may recover and enter log phase growth. This stage of cell growth could make lymphoma cells more vulnerable to a combination of antimetabolite treatment. As the main dose-limiting toxicity for both MTX and Ara-C is myelosuppression, a myeloprotection-based gene therapy strategy with this fusion gene would allow administration of higher doses and more effective treatment with these drugs. We tested this hypothesis, by asking if residual lymphoma cells could be eradicated with post-transplant MTX/Ara-C in a NOD/SCID-human lymphoma xenograft model. 162 NOD-SCID animals bearing measurable tumor tolerated post-transplant treatment with a supralethal-dose MTX/ Ara-C and treatment was curative when animals were treated at an early stage after BM transplant when the tumor burden was minimal (Fig 1) . Baseline gene expression levels were about 5% and post-transplant MTX/Ara-C administration increased fusion gene expressing peripheral blood leukocytes five-to seven-fold during the recovery phase, but this increase was temporary. Thus, transfer of this drug resistance fusion gene into mouse HSCs increased the safety of post-transplant MTX/Ara-C and increased the therapeutic index for the xenografted human lymphoma. 162 Secondary marrow transplants from the fusion gene carrying animals also provided myeloprotection against repeated cycles of supralethal doses of MTX/Ara-C, and transgene expression in peripheral blood leukocytes also increased temporarily after each cycle of combination treatment. Previous studies indicated that anti-folate resistance provided by a single mutant DHFR can be selective at the HSC level in mice treated with trimetrexate and nitrobenzylmercaptopurineriboside-phosphate (NBMPR-P). 73, 175 NBMPR-P inhibits thymidine uptake by murine HSCs, thereby sensitizing unmodified HSCs to anti-folate drugs. However, the same group reported only transient selection of the vector-expressing cells with TMX and NBMPR-P treatment in six rhesus macaques, when animals were transplanted with CD34 þ cells transduced with DHFR vectors. 176 As MTX and Ara-C are not toxic to quiescent marrow stem cells, but are potent inhibitors of cycling marrow progenitors, this combination therapy would not generate any selective pressure on transgene carrying HSCs. This may be an advantage for chemotherapy protection strategies, as only temporary protection is the goal, and having less of a selection advantage at the HSC level might actually decrease the chance of long-term leukemogenic transformation due to gene transfer.
Our NOD/SCID data would indicate that even protection from drug toxicity at the hematopoietic progenitor level will allow us to increase the dose of MTX/Ara-C to a level that might eradicate residual lymphoma. 162 These promising results have led us to plan a clinical trial with a retroviral vector containing the F/S DHFR-CD fusion gene in patients with poor-risk diffuse large cell lymphoma or mantle cell lymphoma who have relapsed or are refractory to first-line therapy.
Drug resistance gene transfer for selective expansion
Therapeutic gene replacement for inborn errors, such as hereditary immunodeficiencies, that is, adenosine deaminase deficiency 12,177,178 and chronic granulomatous Table 2 summarizes the characteristics of retroviral, lentiviral, and foamy viral vectors. [35] [36] [37] 194 However, even with the best gene transfer conditions, the number of transduced HSCs is limited, which is actually a fraction of the whole hematopoietic niche. Additionally, after HSC transplant, there is a rapid regeneration to normal pretransplantation levels in the number of hematopoietic progenitors and mature end cells, whereas HSC numbers recover to only 5-10% of normal levels. 195 HSCs are intrinsically restricted in their self-renewal behavior and hence in their ability to repopulate the host stem cell compartment. Further, in nonmyeloablative conditions, transduced cells are diluted by the large number of untransduced cells. Although corrective HSC gene therapy strategies were suggested to provide selective advantage to the transgene carrying HSCs, transgene carrying HSCs are more prone to immune elimination. [18] [19] [20] [21] [22] 31 For inherited disorders, correction of the phenotype requires a substantial level of gene expression. Selection by incorporating a selectable marker in addition to a therapeutic gene could help to increase the proportion of genetically modified blood cells, and subsequently the therapeutic outcome.
The MDR1 gene, as a selective marker, has been utilized for coexpressing a variety of inherited disorderrelated genes. [196] [197] [198] [199] [200] Paclitaxel administration not only increased gp-91 expression in peripheral blood leukocytes of mice transplanted with Ha-MDR-IRES-gp91-transduced cells, but also led to the sustained expression of the transgenes for over a year. 196 However, in a canine model that used a bicistronic retroviral vector construct coexpressing MDR1 and human IL-2 receptor common gamma-chain cDNAs, paclitaxel treatment restored expression of the transgenes in only one of the dogs, while the other two of the dogs treated with higher doses of paclitaxel succumbed to myelotoxicity. 199 Apparently, any selective pressure strategy has to define the drug doses that will be applied clinically according to the relevant therapeutic index increase correlated to the starting levels of gene-modified cells.
The muMGMT is the most powerful selective drug resistance gene defined so far, and muMGMT provides a survival advantage and extensive selection to the transduced HSCs, even when limited numbers of transgene carrying cells are transplanted or following a nonmyeloablative conditioning. 134, 138, 201 In the b-thalassemic murine model, mice receiving gamma-globin/MGMT dual genetransduced BM following a nonmyeloablative conditioning regimen, temozolomide and BG treatment, had increased red cell gamma-globin, and consequently increased donor cell and hemoglobin levels in the recipient mice. 202 In the absence of drug selection, donor cells contributed to hematopoiesis marginally, and there was no improvement in hemoglobin levels. In an erythropoietic porphyria mouse model, dual expression of ferrochelatase and muMGMT resulted in a progressive increase in gene carrying red blood cells following BG/BCNU treatment. 112 The main concern about the usage of muMGMT as a selectable marker is increased mutagenesis through either the selection of high vector copy number carrying HSCs, or the mutagenic effects of the nitrosoureas. However, the concern about increasing the risk of oncogenesis by selection has not been proven to be true, as drug selection with BG/BCNU did not preferentially increase the survival of high-copy-number clones. 137 In a canine model of gene therapy, selection pressure with BG/BCNU combination did not alter the polyclonal nature of hematopoiesis in animals transplanted with MGMT (P140K)-transduced autologous CD34( þ )-selected cells, and in long-term follow-up there were no signs of myelodysplasia or leukemia. 203 Mutant DHFR might serve as a selectable marker in case an inhibitor of nucleoside salvage pathway is used in combination with anti-folates. 73, 175, 204 In vivo human lysosomal glucocerebridase/muDHFR selection with repeated exposures to MTX has been reported to have modest success in an ablative mouse transplantation model, but the same construct failed to provide any selectable advantage in a nonmyeloablative transplant model. 205, 206 The knowledge we acquired through HSC gene therapy has also revealed that the limitations about expanding the gene-positive HSCs could also be due to intrinsic biological limitation of HSCs. Recently, the same authors who showed successful selection of gamma-globin/MGMT dual gene by drug treatment have reported further expansion of HSC pool when muMGMT was coexpressed with HOXB4 gene. 207 HSCs are significantly restricted in their self-renewal behavior and hence in their ability to repopulate the host stem cell compartment. The mechanisms underlying HSC self-renewal are multifactorial. In HSCs, the cell cycle is regulated by external factors such as cytokines and interactions with stromal cells and the extracellular matrix in the BM microenvironment. Additionally, the transcription factors expressed in HSCs, including c-Myb, GATA-2, HOX family proteins, and Bmi-1, control their growth through their effect on gene transcription. 208 The HOX family of homeobox genes have a role in embryonic development and have important functions in hematopoiesis. HOXA and HOXB genes are expressed in human CD34 þ cells, and are downregulated as cells leave the CD34 þ compartment. Overexpression of HOXB4 results in a dramatic expansion of HSCs, while maintaining normal peripheral blood counts. 209 Serial transplantation studies revealed that HOXB4 overexpression has a profound impact on HSC compartment renewal (50 Â higher numbers of transplantable HSCs) in primary and secondary recipients. 209 In mouse models, HOXB4-transduced HSCs are capable of fully reconstituting the HSC compartment, indicating that HOXB4 is a limiting factor in the regeneration of HSCs to normal levels after HSC transplant. HOXB4 appears to be a strong positive regulator of HSC self-renewal without impairing homeostatic control of HSC population size or the rate of production and maintenance of mature end cells. HOXB4 transduction into HSCs enabled rapid, extensive, and highly polyclonal HSC expansions (40 Â ), while control GFP-transduced murine BM cells experienced large HSC losses over 10-14 days. These HSCs retained full lympho-myeloid repopulating potential and enhanced in vivo regenerative potential. 210 Thus, HOXB4 is a particularly attractive candidate for use in HSC expansion either ex vivo or in vivo. Forced expression of HOXB4 by inclusion of HOXB4 cassette in the DHFR or MGMT vectors overcame the reduction in HSC numbers after in vivo drug selection, and increased the HSC selection efficiency. 207 A concern is that although leukemia has not been detected in mouse models, HOXB4 gene transfer in human HSCs could be harmful. HOX proteins have the ability to passively translocate through the cell membranes. A recombinant human TAT-HOXB4 protein carrying the protein transduction domain of the HIV transactivating protein (TAT) has been recently synthesized. 211 HSCs exposed to TAT-HOXB4 for 4 days expanded at comparable levels to that induced by a human HOXB4 retroviral construct, and TAT-HOXB4-expanded HSC populations retained their normal in vivo potential for differentiation and longterm repopulation. 211 Incorporation of methods that will induce in vivo HSC expansion, HOXB4, parathormone, etc, combined with the use of drug resistance genes as selectable markers might increase progress in the treatment of inborn errors.
Recent safety concerns about HSC gene therapy
Vectors designed to integrate into the host genome, that is, retrovirus and lentivirus, are widely used for gene transfer into HSCs. Insertion of ectopic DNA may be mutagenic, as it can alter gene transcription and regulatory and/or coding elements. The inherent insertional oncogenesis feature of retroviral vectors has been used for generating experimental tumor models to understand the genetic basis of cancer. [212] [213] [214] [215] Retroviral or lentiviral integration is not sequence specific, thus all chromosomal sites are suggested to be prone to integration events, but in vivo-integrated viruses were preferentially detected in open chromatin regions, that is, transcriptionally active sites in the vicinity of cellular promoters. [216] [217] [218] Although the potential risk of insertional oncogenesis has been a concern, 219 there have been few reports documenting insertional oncogenesis. 220 However, this assumption was challenged when leukemia transformation in three patients was reported in a gene therapy trial for X-SCID. [68] [69] [70] In the gene therapy trial for X-SCID, purified BM CD34 þ cells were transduced by amphotropic retroviral particles containing a MoMLVbased vector encoding g c cDNA under the transcriptional control of LTR. The patients have shown clear signs of clinical improvement with increased levels and repertoire of immune effector cells and reduced episodes of infection. 185, 221 The transgene provided a survival and proliferative advantage to gene-corrected cells, as the genetic defect in X-SCID affects the gamma chain that is common to a number of cytokine receptors, and this lack of functional activity of these cytokine receptors reduces survival and maturation of lymphoid cells. However, this survival advantage in combination with the vector integration near LMO-2 site, an oncogene associated with T-ALL, consequently played a role in dysregulated growth of transgene-positive clones and two patients developed T-cell leukemia 30-34 months after the transplant. 68, 69 It was suggested that the g c transgene contributed either additively or synergistically to LOM-2-related leukemogenesis. 222 Thus far, in large animals including 17 dogs and 65 non-human primates, 223 and more than 200 patients treated with retrovirally transduced CD34 þ cells, even with a similar vector backbone, no oncogenic event has been reported. 220 However, there is not enough data for a reliable risk assessment of malignant adverse events, as the follow-up has not been long enough. The mutagenesis risk of retroviral gene transfer has to be balanced with consideration of the risk/benefit ratio. High vector copy numbers per cell are known to increase insertional mutagenesis, and recent data provided a quantitative correlation with gene transfer rates and integration frequency. As for gene transfer rates less than 30%, there was approximately one vector copy per cell, limiting the transduction rates to around 30% was recommended. 224 Prospective evaluation of retroviral insertion sites with linear amplification PCR (LAM-PCR) has been considered as an essential part of monitoring after gene therapy. LAM-PCR is an informative test more than a diagnostic one. However, having a stable pattern of oligo/monoclonal integration does not always imply an increased risk for malignant hematopoiesis, 225 and the human hematopoietic stem cell pool has intrinsic heterogeneity, 17 which effects LAM-PCR read-outs. However, systematic monitoring of integration sites and generation of a database are required to further understand the mechanism of insertional mutagenesis, and to provide new insights, enabling safer and more effective gene therapy strategies.
Conclusions
The next few years should see a renewed interest in the use of drug resistance genes to protect marrow from myelotoxicity. A safe, reproducible method to introduce drug resistance genes into HSCs will clearly stimulate this field, as well as the availability of a wide variety of drug resistance genes for this purpose. In order to use drug resistance genes as dominant selectable markers, safety concerns are to be addressed. This concern has led to long and rigorous reviews by institutional committees as well as the RAC and the FDA. The need for GMP facilities and oversight, and long-term follow-up requirements necessitates better financial and technical support for clinical gene therapy trials. The National Gene Vector Laboratory has been an important resource in providing vectors and safety tests for clinical studies. 
